Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer

Table 1

Characteristics and outcome of patients in the series. Column “All patients” includes the whole series of patients with normal platelets or thrombocytosis. 𝜒² test between the group with normal platelet count and the group with thrombocytosis is shown. Wherever there are more than two categories, the grouping of the comparison is mentioned in the same column. Her-2 was defined as positive if 3+ by IHC or amplified by FISH and negative if 1+ by IHC or 2+ by IHC and FISH not amplified or not performed.

	All patients	normal	thrombocytosis	𝜒^2
Number (%)	165 (100)	135 (81.8)	30 (18.2)
Age at diagnosis of metastatic disease
Median (range)	62 (31–92)	62 (31–92)	66 (44–85)
>65 years	70 (42.4)	54 (40)	16 (53.3)	𝑃=0.17
≤65  years	95 (57.6)	81 (60)	14 (46.7)
ER/PR				Positive versus negative; 𝑃=0.69
Positive (either or both)	126 (76.4)	102 (75.5)	24 (80)
Negative (both)	37 (22.4)	31 (23)	6 (20)
Unknown	2 (1.2)	2 (1.5)	0
Her-2				Positive versus negative; 𝑃=0.35
Positive	35 (21.2)	27 (20)	8 (26.7)
Negative	107 (64.9)	90 (66.7)	17 (56.7)
Unknown or ambiguous	23 (13.9)	18 (13.3)	5 (16.6)
Grade				III versus I and II; 𝑃=0.42
I	10 (6.1)	8 (6)	2 (6.7)
II	66 (40)	55 (40.7)	11 (36.6)
III	67 (40.6)	52 (38.5)	15 (50)
Unknown	22 (13.3)	20 (14.8)	2 (6.7)
Metastatic at diagnosis
Yes	67 (40.6)	46 (34.1)	21 (70)	𝑃=0.0003
No	98 (59.4)	89 (65.9)	9 (30)
Sites of metastases				Bone only versus other; 𝑃=0.81
Bone	41 (24.9)	34 (25.2)	7 (23.3)
Soft tissue	21 (12.7)	20 (14.8)	1 (3.3)
Parenchymal	38 (23)	34 (25.2)	4 (13.4)
Multiple sites	65 (39.4)	47 (34.8)	18 (60)
1st metastatic treatment
None or hormonotherapy	74 (44.8)	63 (46.7)	11 (36.7)	𝑃=0.32
Chemotherapy	91 (55.2)	72 (53.3)	19 (63.3)
Adjuvant treatment
None or hormonotherapy	52 (53.1)	47 (52.8)	5 (55.6)	𝑃=0.87
Chemotherapy	46 (46.9)	42 (47.2)	4 (44.4)